July 11, 3:50 PMVaccines ExaminerNorma Erickson
According to a recent abstract in PubMed, 56 experts in cervical cancer gathered to review the current state of HPV typing in the vaccinated population of the United States and the potential for typing this population over the next five years.
Their conclusions were startling, to say the least. On one hand, they conclude that HPV DNA screening and genotyping may be the future in the post-HPV vaccination United States.
On the other hand, they state, “HPV typing should not be used to determine who should be vaccinated against HPV.”
Anyone who has an ounce of common sense, has to ask why not?
If someone is already exposed to a vaccine-relevant strain of HPV prior to vaccination, their chance of getting precancerous lesions/cancer increases between 30% and 44.6%, depending on which brand of vaccine is administered. (Read: Warning, Gardasil may cause increased risk of cervical cancer.)
As a consumer looking at vaccines that may reduce your risk of cancer, knowing whether or not you have been exposed to vaccine-relevant strains of HPV is critical. If you have already been exposed, you may not know it. You may have no symptoms. Wouldn’t it be worth taking a simple test to find out if you have been exposed prior to vaccination so as not to increase your potential risk? Why should HPV genotyping not be used pre-vaccination?